Inhibikase Therapeutics (IKT) Interest Expenses (2020 - 2022)
Inhibikase Therapeutics (IKT) reported Interest Expenses of $5.0 for Q1 2022, down 99.96% year-over-year from $11797.0 in Q1 2021, and down 96.84% quarter-over-quarter from $158.0 in Q4 2021.
Inhibikase Therapeutics (IKT) Interest Expenses (2020 - 2022) Analysis & Trends
Inhibikase Therapeutics (IKT) has 3 years of Interest Expenses data on file, last reported at $5.0 in Q1 2022.
- Interest Expenses for Q1 2022 came in at $5.0, down 99.96% year-over-year; the trailing twelve-month figure through Dec 2022 was $5.0 (down 99.97% YoY), and the FY2021 annual result was $19923.0, down 32.24% from the prior year.
- Interest Expenses fell to $5.0 in Q1 2022 per IKT's latest filing, from $158.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $11797.0 in Q1 2021 and troughed at $5.0 in Q1 2022.
- A 3-year average of $5481.1 and a median of $7139.0 in 2020 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2021 and 2022: Interest Expenses jumped 58.88% in 2021, then tumbled 99.96% in 2022.
- A 3-year view of Interest Expenses shows it stood at $7139.0 in 2020, then sank by 97.79% to $158.0 in 2021, then slumped by 96.84% to $5.0 in 2022.
- Business Quant data shows IKT's Interest Expenses at $5.0 in Q1 2022, $158.0 in Q4 2021, and $157.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 61,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -332,000.00 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -5.58 Mn |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 5.00 |
| Mar 31, 2022 | 5.00 |
| Dec 31, 2021 | 158.00 |
| Dec 31, 2021 | 158.00 |
| Sep 30, 2021 | 157.00 |
| Sep 30, 2021 | 157.00 |
| Jun 30, 2021 | 7,811.00 |
| Jun 30, 2021 | 7,811.00 |
| Mar 31, 2021 | 11,797.00 |
| Mar 31, 2021 | 11,797.00 |
| Dec 31, 2020 | 7,139.00 |
| Dec 31, 2020 | 7,139.00 |
| Sep 30, 2020 | 6,890.00 |
| Sep 30, 2020 | 6,890.00 |
| Jun 30, 2020 | 7,948.00 |
| Jun 30, 2020 | 7,948.00 |
| Mar 31, 2020 | 7,425.00 |
| Mar 31, 2020 | 7,425.00 |